Multiple innate immune and metabolic targets

The term Multiple innate immune and metabolic targets refers to a broad pharmacological profile rather than a single discrete protein or receptor (Nature Reviews Immunology, 2017). It encompasses a variety of molecular pathways that link cellular metabolism with innate immune signaling, a field known as immunometabolism (Cell Metabolism, 2016). Common targets within this category include the NLRP3 inflammasome, adenosine monophosphate-activated protein kinase (AMPK), and the mechanistic target of rapamycin (mTOR) (Nature, 2017). Drugs described as hitting these multiple targets, such as metformin or hydroxychloroquine, are often pleiotropic agents used to treat chronic inflammatory conditions, metabolic syndrome, and certain autoimmune disorders (The Lancet, 2020). Because this is a collective designation for a group of unrelated or loosely related proteins, it does not possess a single canonical structure or specific molecular classification. Consequently, it is considered an incorrect or overly broad entry for a specific therapeutic target database.

Other names

Immunometabolic targetsInnate immune and metabolic pathwaysMetabolic and immune targets

Modulation of multiple pathways including AMPK activation, inflammasome inhibition, and metabolic reprogramming of immune cells.